Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation.

Arch Dermatol Res · 2023 · PMC9813067 · PMID 35032198

Europe PMC DOI

hedged sentence

0.0630

closest p · 1.3× alpha

0.0630

boldest claim

The sentences

a trend towards significanceP = 0.063so close (0.05 < p ≤ 0.1)

[ 17 ] revealed that patients with DPP4i-associated BP had higher total BPDAI scores with a trend towards significance (41.0 vs. 34.1; P = 0.063).

also in 2,760 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.